Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies

Shu Fang; Nan Wang; Lili Wang; Jishan Du; Jingjing Yang; Yanan Wen; Yan Wei; Kun Qian; Hao Wang; Yifan Jiao; Chunji Gao; Liping Dou

doi:10.12659/AOT.937356

11 October 2022 : Original article

Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies

Shu Fang^12ABCDEF, Nan Wang^23ABCF, Lili Wang^2ABCD, Jishan Du^23BCF, Jingjing Yang^23BCF, Yanan Wen^23BCF, Yan Wei^23BCF, Kun Qian^12BCD, Hao Wang^23ABF, Yifan Jiao^23BCF, Chunji Gao^12ACEG*, Liping Dou^2ABDEG

DOI: 10.12659/AOT.937356

Ann Transplant 2022; 27:e937356

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 5 Univariate analysis of risk factors for moderate to severe cGVHD and CIR in all patients.

	Moderate to severe cGVHD			CIR
	HR	95% CI	p	HR	95% CI	p
ATG vs non-ATG	0.301	0.099–0.918	0.035	2.158	1.051–4.430	0.036
Recipient age (≥ median vs < median)	0.407	0.152–1.084	0.072	1.405	0.687–2.875	0.352
Donor age (≥ median vs < median)	0.591	0.229–1.526	0.278	1.633	0. 798–3.343	0.180
Donor-recipient gender match
Female to male vs others	1.438	0.556–3.720	0.454	1.125	0.542–2.334	0.752
Donor-recipient ABO match
Mismatch vs match	0.907	0.340–2.420	0.846	1.405	0.699–2.827	0.340
Diagnosis (ALL vs others)	0.765	0.250–2.343	0.639	1.701	0.830–3.489	0.147
Time interval between diagnosis and HSCT
≥6 m vs <6 m	0.737	0.291–1.872	0.521	0.577	0.282–1.181	0.132
Cytogenetic risk
High vs favorable/intermediate	0.434	0.125–1.499	0.187	1.147	0.543–2.424	0.719
Disease status at HSCT
Untreated/refractory/relapsed vs CR	1.300	0.428–3.953	0.644	1.170	0.506–2.706	0.714
Disease risk index
High/very high vs low/intermediate	0.418	0.121–1.443	0.168	1.610	0.794–3.264	0.187
MNC (≥ median vs < median)	0.789	0.311–2.001	0.618	1.159	0.579–2.322	0.677
CD34 (≥ median vs < median)	0.829	0.326–2.107	0.694	1.548	0.763–3.141	0.226
aGVHD (Grades 2–4 vs grades 0–1)	0.700	0.249–1.968	0.499	2.158	1.051–4.430	0.036
ATG – anti-thymocyte globulin; aGVHD – acute graft-versus-host disease; cGVHD – chronic graft-versus-host disease; CIR – cumulative incidence of relapse; HSCT – hematopoietic stem cell transplantation; ALL – acute lymphoblastic leukemia; CR – complete remission; MNCs – mononuclear cells.

Back to the Article

Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies

Your Privacy